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Abstract 
Children on dialysis have a cardiovascular mortality risk equivalent to the elderly and develop 
medial vascular calcification, an age-associated pathology. We hypothesized that premature 
vascular ageing contributes to calcification in children with renal failure. 
Vessels from children on dialysis showed elevated oxidative DNA damage and senescence 
markers p16 and p21 and treatment of vessel rings ex vivo with calcifying media increased 
oxidative DNA damage. Vascular smooth muscle cells (VSMCs) cultured from dialysis vessels 
exhibited persistent DNA damage, impaired DNA damage repair and accelerated senescence. In 
response to calcifying conditions dialysis VSMCs showed increased osteogenic differentiation 
and calcification correlating with activation of the pro-inflammatory senescence-associated 
secretory phenotype (SASP).  Blockade of ATM-mediated DNA damage signalling reduced 
both inflammation and calcification, consistent with a role for the SASP in calcification.  
Clinically, children on dialysis showed elevated circulating levels of key osteogenic SASP 
factors, BMP2, OPG and IL6 that correlated with increased vascular stiffness and coronary 
artery calcification.   
These data imply that dysregulated mineral metabolism drives vascular ‘Inflammaging’ by 
promoting oxidative DNA damage, premature senescence and activation of a pro-inflammatory 
SASP. Drugs that target DNA damage signalling or senolytics may be therapeutic agents for the 
prevention of vascular calcification. 
 
Key Words: dialysis, senescence, vascular smooth muscle cells, aging, calcification. 
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Introduction 
Age is the dominant risk factor for cardiovascular disease and medial vascular 
calcification is a prevalent, age-associated pathology. Medial calcification is also a prominent 
pathology in patients with chronic kidney disease (CKD) and progresses rapidly in patients on 
dialysis1-3. Medial calcification is associated with increased vascular stiffening and cardiac work 
load, poor coronary perfusion and sudden cardiac death and is thought to be responsible for the 
high cardiovascular mortality observed in CKD patients4.  Significantly, even children and 
adolescents on dialysis develop vascular calcification and have a vastly elevated risk for 
cardiovascular mortality when compared to the normal age matched population.  Strikingly, the 
risk in adolescence is equivalent to that of the very elderly in the general population2, 5. The clear 
association between ageing and vascular calcification in the general population has led to the 
suggestion that CKD patients may exhibit accelerated vascular ageing however, so far, there is 
little direct molecular evidence to support this notion6, 7.  
A key event leading to cellular ageing is the accumulation of un-repairable or persistent 
DNA damage8, 9. DNA damage increases with age and factors such as oxidative stress can 
accelerate ageing in part, by promoting oxidative DNA damage10-12.  Persistent DNA damage 
signalling, via key transducers such as the kinase ataxia-telangiectasia mutated (ATM), 
promotes upregulation of the checkpoint cell cycle inhibitors p16 (CDKN2A/INK4a) and/or p21 
(CDKN1A) leading to cell cycle arrest and ultimately to cellular senescence13.  Senescent cells 
are viable but can no longer contribute to repair processes. Importantly, they display an 
inflammatory phenotype termed the senescence associated secretory phenotype (SASP) 
characterized by the secretion of an array of pro-inflammatory cytokines, and growth factors as 
well as proteases that can act in a paracrine fashion to influence remote cells and tissues14.  DNA 
damage and cellular senescence have recently been reported to promote osteogenic 
differentiation of VSMCs suggesting there may be a direct link between ageing and 
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calcification, however, the mechanisms involved as well as evidence for this process in vivo is 
still limited15, 16.   
In CKD non-traditional risk factors such as dysregulated calcium (Ca) and phosphate (P) 
metabolism accelerate vascular calcification by promoting VSMC death and osteogenic 
differentiation17, 18.  There is also evidence to suggest that dysregulated mineral metabolism, and 
in particular elevated P, can drive premature ageing19.  Fibroblast Growth Factor 23 (FGF23) 
and its obligate co-receptor Klotho are major physiological regulators of Ca and P metabolism20.  
Mice deficient in either of these proteins develop an array of age-associated pathologies 
including osteoporosis, vascular calcification and premature death in the context of 
hypercalcemia, hyperphosphatemia and vitamin D dysregulation 21, 22. Importantly normalization 
of mineral metabolism can alleviate premature ageing in these models.  Elevated P is also 
associated with increased cardiovascular calcification and mortality in ageing populations23 
however, the molecular events linking ageing and calcification with dysregulated mineral 
metabolism are not understood.   
Children make an ideal model for studying accelerated ageing. They are not confounded 
by long-term exposure to environmental stresses that complicate the interpretation of ‘ageing’ 
measures in adults. In the context of CKD, vascular damage and calcification occurs almost 
exclusively due to the complications of renal failure, rather than smoking, dyslipidaemia or pre-
existing cardiovascular disease that are prevalent in adults with CKD. Dysregulated mineral 
metabolism is a key cause of vascular calcification in children on dialysis24 and we recently 
reported accumulation of the ageing biomarker prelamin A in the calcified arteries of these 
children15, 25. Prelamin A interferes with DNA damage repair leading to accelerated VSMC 
senescence and activation of the SASP15, 26. This toxic nuclear protein also accumulates in the 
calcified vasculature of aged adults and is causal in the induction of accelerated vascular 
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calcification and stiffening in children with the premature ageing disorder Hutchinson-Gilford 
Progeria Syndrome27, 28.   
We hypothesized that vessels from children with CKD are prematurely aged and that 
persistent DNA damage leading to premature senescence may be a key event in driving 
accelerated calcification.  We examined evidence for vascular ageing and senescence in children 
both in vitro and in vivo and correlated these with clinical vascular measures.  We found direct 
evidence for premature VSMC ageing and define a potential role for DNA damage signalling 
and ‘inflammaging’ in driving vascular calcification in children with CKD.  
 
Results 
Vessels from CKD children show premature vascular ageing 
Medium-sized muscular arteries were harvested from children in pre-dialysis CKD stage 
5 (CKD5) and on dialysis (CKD5D), as well as healthy controls (Table S1).  An antibody to 8-
oxo-dG that recognises oxidatively modified DNA showed that vessels from control patients had 
low levels of oxidative DNA damage as expected in young children.  In contrast, vessels from 
children with CKD5-5D showed significantly elevated levels of oxidative DNA damage (Fig 
1A). Compared to controls, vessels from CKD5-5D patients also showed elevated levels of the 
senescence marker p21. However, p16 was significantly increased only in dialysis vessels with 
levels in CKD5 patients highly variable (Figure 1 B,C). 
 
VSMCs from children on dialysis show elevated levels of DNA damage and premature 
senescence in vitro 
VSMCs were explanted from control and CKD5-5D vessels and compared during serial 
passaging in vitro. There was marked variability in growth potential between different CKD5-
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5D isolates (Table S2 and Figure S1) but commonly, VSMCs explanted from CKD patients 
grew more slowly and senesced at earlier passages than control cells (control; passage >30 vs 
CKD; passage 16.4+/-10.1) (Figure 2A and B). Senescence was demonstrated using senescence 
associated β-galactosidase (SAβG) staining and observation of an enlarged, flattened, cell 
morphology (Figure 2B).  On Western blot VSMCs approaching senescence showed elevated 
levels of p16 with variable levels of p21 suggesting senescence was mediated by p16 in vitro 
(Figure 2C). 
To assess whether the limited growth potential of CKD VSMCs was associated with 
DNA damage, immunofluorescence staining for the DNA damage response (DDR) signalling 
markers γH2AX and pATM/ATR substrate was performed. VSMCs cultured from dialysis 
patients showed increased DNA damage compared with CKD5 or controls at equivalent passage 
number (Figure 2D,E). Elevated levels of DNA damage signalling in dialysis VSMCs was 
confirmed by Western Blot performed on a limited number of cell isolates that had not been 
subjected to freeze/thaw cycles during culture, in order to limit any potential bias towards 
selection of healthy cells. Levels in control and CKD5 VSMCs were low and equivalent (Figure 
2F). Comet assays were used to determine whether the elevated DNA damage signalling 
observed in dialysis VSMCs was due to unrepaired DNA double strand breaks. This was 
confirmed as comet tails were observed in dialysis VSMCs and were mainly absent in control 
cell nuclei (3.5 +/- 1.3% control versus 37.1+/-1.2% dialysis) (Figure 2G).  
 
Ca and P induce oxidative stress and DNA damage in VSMCs. 
To test whether dysregulated mineral metabolism might contribute to DNA damage, 
control VSMCs were treated with calcifying media containing elevated levels of Ca/P.  
Increased levels of DNA damage, shown by γH2AX nuclear foci and protein on Western Blot 
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were observed at levels equivalent to those induced by hydrogen peroxide and doxorubicin, both 
of which induce oxidative DNA damage (Figure 3A-C). Lucigenin assays demonstrated that 
calcifying media induced hydrogen peroxide production in VSMCs suggesting oxidative DNA 
damage may be responsible for the increased levels of DNA damage signalling observed (Figure 
S2).  
To examine further the role of Ca/P in the induction of DNA damage, vessel rings from 
control and CKD patients were exposed to calcifying medium for 7 days ex vivo and levels of 8-
oxo-dG staining quantified.  Vessel rings from control patients were relatively resistant to the 
induction of oxidative DNA damage and did not show a significant elevation in staining.  In 
contrast, VSMCs in CKD5-5D showed significantly elevated 8–oxo-dG staining after Ca/P 
treatment, with dialysis vessels showing the greatest accumulation over the time period tested 
(Figure 3D,E).  
To explore the mechanism of increased susceptibility to DNA damage observed in 
dialysis VSMCs we treated control and dialysis VSMCs with an acute dose of doxorubicin and 
examined levels of DNA damage before and after washout, to quantify the efficiency of DNA 
damage repair. The DNA damage response was similar in control and dialysis VSMCs after 2 
hours, however, 24 hours after washout control cells showed a greater efficiency of repair 
evidenced by fewer γH2AX foci (Figure 4A).  At this stage dialysis VSMCs also showed 
evidence for persistent DNA damage with a higher percentage of cells retaining >5 53BP1 
nuclear foci consistent with a reduced repair capacity in these cells (Figure 4B). 
 
DNA damage and senescence drive increased calcification and the pro-inflammatory SASP in 
dialysis VSMCs 
	8		
Given the clear differences in the DNA damage response between control and dialysis 
VSMCs we next used qRT-PCR to compare gene expression at equivalent early passage 
numbers between these two cell types. At baseline in normal media, levels of the senescence 
marker p16 were not different. However, VSMCs from dialysis patients had decreased levels of 
the differentiation marker α-SM actin and elevated expression of the osteogenic morphogen 
BMP2, as well as Runx2 and BSP, although these did not reach significance (Figure 5A). In 
response to calcifying media VSMCs from dialysis patients showed greater mineralization 
(Figure 5B).  This was associated with increased expression of the osteogenic marker Runx2 and 
dramatically elevated BMP2 expression compared to controls (Figure 5C).  
We previously identified BMP2 as a SASP factor in adult aortic VSMCs15 so we next 
tested whether elevated Ca/P might accelerate senescence in dialysis VSMCs.  SAβG staining 
showed a small but significant increase in the number of senescent cells after short-term 
treatment (16 hours) with calcifying media in dialysis but not in control VSMCs. Of note, 
treatment with P alone was sufficient to increase the number of senescent cells (Figure 6A and 
B). Western blot showed that Ca/P media consistently increased the expression of p16 in dialysis 
VSMCs, in contrast to control VSMCs where no pattern was observed (Figure 6C).  Western 
blot also confirmed elevated BMP2 in dialysis compared to control VSMCs in both normal and 
calcifying conditions (Figure S3).  
To examine in more detail the inflammatory SASP profile of control and dialysis 
VSMCs, antibody arrays were performed comparing conditioned media from equivalent early 
passage cells.  A number of previously identified SASP factors were found to be abundantly 
secreted by VSMCs including the cytokines IL6, IL8, OPG and MCP-1 and the protease 
inhibitors TIMP1 and TIMP2 (Figure S4A,B).  Dialysis VSMCs secreted elevated levels of a 
number of these factors compared to control cells including IL6, IL8 and OPG and also secreted 
elevated levels of the chemokines CSF2, CXCL1 and CXCL3 although of these, only CXCL3 
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was relatively abundant (Figure S4B,C).  qRT-PCR analysis was used to verify that BMP2, IL6 
and OPG were all more highly expressed by dialysis VSMCs compared with controls and 
increased secretion of IL6 and OPG was confirmed using ELISA  (Figure 7C and Figure S5).   
To determine whether DNA damage signalling acting upstream of the inflammatory 
SASP was responsible for the increased calcification observed in dialysis VSMCs, both dialysis 
and control cells were treated with either an siRNA or a chemical inhibitor (Ku55933) targeting 
ATM, a key signalling kinase in the DNA damage response.  ATM inhibition reduced the 
accelerated calcification observed in dialysis VSMCs (Figure 7A and B).  Importantly the 
reduced calcification observed in dialysis VSMCs was mirrored by the pattern of expression of 
the SASP markers BMP2, IL6 and OPG; ATM inhibition significantly decreased their 
expression in dialysis cells consistent with their activation in response to persistent DNA 
damage (Figure 7C).  
 
CKD children show elevated levels of circulating SASP factors correlating with vascular 
ageing measures. 
Three of the SASP factors elevated in dialysis VSMCs, BMP2, OPG and IL6, have 
previously been shown to play a role in regulating calcification15.  Therefore we quantified the 
serum levels of these factors in children with CKD5-5D, correlating these biochemical 
measures with vascular scans.  Serum BMP2, OPG and IL6 levels did not depend on age or 
gender in children.  However, both IL6 and BMP2 levels were significantly higher in dialysis 
versus the CKD5 group (Figure 8A,B), and IL6 levels increased with increasing time on 
dialysis (Figure S6A). The circulating levels of BMP2 and OPG correlated with arterial 
stiffness measured by aortic pulse wave velocity, a surrogate marker of medial calcification 
(Figure 8C,D).  Moreover, levels of IL6 correlated with both BMP2 and OPG suggesting 
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increases in these cytokines may occur concomitantly (Figure S6B,C).  Importantly, comparing 
CKD children with coronary artery calcification measured by multi-slice CT scan (n = 8) 
against those who did not show calcification (n = 16), there was an increase in these secreted 
SASP factors in patients with overt calcification (Figure 8E) suggesting that the paracrine 
release of these factors may be clinically relevant. 
 
Discussion 
In this study we show that vessels from children with CKD exhibited features of 
premature ageing in vivo including oxidative DNA damage and elevated senescence markers 
and these ageing indices persisted upon culture of VSMCs in vitro.  Ca/P treatment was shown 
to increase DNA damage in CKD vessel rings ex vivo and to drive senescence of dialysis 
VSMCs in vitro. The persistent DNA damage observed in dialysis VSMCs was associated with 
increased osteogenic differentiation and calcification driven in part, by activation of the pro-
inflammatory SASP. Importantly, a number of these SASP factors, previously identified as pro-
calcific, correlated with increased PWV and were significantly increased in the serum of 
children with clinically measurable calcification.  Taken together, these data suggest that the 
paracrine secretion of inflammatory/osteogenic factors by aged VSMCs may be an important 
driver of arterial stiffening and vascular calcification in CKD.  We suggest that the onset of 
VSMC senescence may be a key ‘set-point’ driving the rapid progression of this age associated 
pathology in young CKD patients. Importantly it may be that only a few senescent VSMCs are 
required to initiate this cascade. 
 
VSMCs from children with CKD show hallmarks of premature ageing 
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We demonstrated that CKD and in particular, the dialysis environment, is associated 
with increased oxidative DNA damage and premature senescence of VSMCs in vivo. While 
studies have shown that oxidative DNA damage and the senescence markers p16 and p21 are 
elevated in atherosclerotic plaque and adult vessels from CKD patients11, 29, 30 this is the first 
study to show increased levels of these markers in vessels from young children, who are free of 
confounding factors including atherosclerosis, providing compelling evidence that the vascular 
pathology observed in these patients is closely associated with premature ageing31, 32. Our data 
suggests that oxidative DNA damage accrual begins in predialysis CKD5, as levels of 8-oxo-dG 
and p21 were significantly elevated at this stage, but is accelerated in the dialysis milieu leading 
to unrepaired DNA damage and stress induced premature senescence a hallmark of which is p16 
accumulation29,31.  
 
Dysregulated mineral metabolism promotes oxidative DNA damage and premature 
senescence in dialysis VSMCs. 
A major signal driving oxidative DNA damage was Ca and P stress.  Osteogenic media 
induced oxidative DNA damage in CKD5-5D vessel rings cultured ex vivo, with control vessels 
showing some resistance to the same stimulus.  This is consistent with our previous studies 
showing that dialysis vessels, and to a lesser extent CKD5 vessels, undergo VSMC death, 
osteogenic differentiation and calcification when cultured ex vivo in Ca/P media, providing 
further support for a link between premature ageing and calcification24, 33. There are a number of 
potential mechanisms, that are not mutually exclusive, that may explain why dialysis patient 
VSMCs show increased susceptibility to Ca/P stress. We showed that osteogenic media induced 
DNA damage and accelerated senescence of dialysis VSMCs in vitro and that these cells 
showed delayed DNA damage repair compared with control cells. Delayed repair may be due in 
part to the reported increased levels of prelamin A in dialysis VSMCs as this nuclear toxin 
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delays DNA damage repair and accelerates senescence15, 26 by sequestering and compromising 
nuclear import of essential DNA repair factors26, 34. Dialysis VSMCs also display decreased 
oxidant defenses35 and this, as well as mitochondrial damage,36 could lead to further elevations 
in reactive oxygen species. Of note, P alone was able to promote senescence of dialysis VSMCs 
and a recent study showed that P may interfere with the expression of a key longevity gene 
Sirtuin1, which deacetylates and inactivates p53, allowing cells to survive DNA damage37.   In 
addition key longevity genes expressed in VSMCs such as Klotho are intimately linked with P 
metabolism and oxidative stress38 and these proteins are downregulated in response to ageing 
and disease suggesting further studies on the regulation and role of these factors in VSMCs are 
warranted39, 40.  
 
Aged VSMCs show increased inflammation, osteogenic differentiation and calcification 
The SASP is a storm of inflammatory cytokines released by cells in response to 
persistent DNA damage signalling41, 42 and previous studies have shown that senescent adult 
aortic VSMCs in vitro upregulate and secrete potent osteoinductive and inflammatory factors 
such as BMP2 and IL6 as part of the SASP response43-45. In this study, we showed that VSMCs 
from children on dialysis, without additional stimulation, expressed and secreted elevated levels 
of these same SASP osteoinductive factors and that Ca/P stimulation increased levels further.  
Furthermore, elevated levels of SASP inflammatory markers correlated with increased 
osteogenic differentiation and calcification of dialysis VSMCs while blocking ATM-mediated 
DNA damage signalling reduced inflammation and calcification. SASP factors including IL6 
and OPG have been reported to be elevated in both adult and paediatric dialysis patient 
cohorts31, 46, 47 while in adult CKD populations increased circulating levels of BMP2 have been 
reported correlating with increased serum 8-oxo-dG levels and vessel wall stiffness48.  It is 
plausible that the systemic release of cytokines from prematurely aged vascular cells may induce 
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a vicious cycle of inflammation and calcification in CKD patients42.  In support of this 
hypothesis, elevated serum IL-6 levels in hemodialysis patients were found to associate with 
aortic calcification and to predict cardiovascular death49, 50.  Moreover, IL6 was a significantly 
better predictor of mortality risk than other inflammation markers such as C-reactive protein, 
albumin or TNFα51.  The presence of SASP factors in the serum of patients on dialysis may also 
explain studies in vitro where dialysis serum promotes calcification of VSMCs and this is 
independent of serum Ca/P levels52.  
 
Limitations and Clinical implications  
This study has a number of limitations that need to be addressed before taking any 
findings forward to clinical interventions.  Although children provide the best model for 
investigating ageing processes tissue retrieval is difficult, hence, the study was limited by small 
sample size.  A key question that was not fully addressed was whether the factors driving 
premature ageing were present in predialysis CKD5 or at even earlier stages of CKD. Although 
the findings suggest that DNA damage does begin predialysis this needs to be confirmed using a 
larger patient cohort. Moreover, the origin of the cells from different vascular beds, children of 
different ages and dialysis vintage, the inherent heterogeneity of the CKD population and the 
phenotypic modulation that takes place in vitro, were all reflected in the behaviour of the 
VSMCs studied, making it impossible to draw further conclusions. The clinical studies were also 
limited by small sample size and the lack of a control group.  The correlations with PWV and 
CAC suggest that inflammation closely follows the onset of vessel stiffening and worsens when 
overt calcification is present.  However extrapolating from peripheral arteries to coronary 
arteries should be viewed with caution although it is likely that in children, who are free of 
atherosclerosis, coronary calcification is also likely to be medial.  
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 Despite these limitations these findings may have important clinical implications 
because they do point to a mechanism whereby elevated oxidative DNA damage in vessels, 
probably starting in predialysis CKD, promotes a cascade of senescence, inflammation and 
calcification.  Studies have shown that oxidant stress occurs in CKD before dialysis therapy is 
initiated53 and increases according to duration of dialysis treatment54, 55 and it is likely that in 
addition to Ca and P, other factors present in the dialysis environment contribute to oxidative 
stress56, 57.  These agents are likely to have a cumulative effect over time as evidenced by the 
increased senescence markers found in dialysis vessels, thus highlighting the need to monitor 
and maintain Ca and P levels within the age-appropriate range starting from CKD558. It also 
highlights that conventional clinical interventions, aimed at correcting circulating risk factors, 
must be complimented by alternate techniques and that drugs targeting alternate pathways such 
as the DNA damage response or senescent cells (senolytics) may be potential therapies to slow 
the progression of vascular calcification and associated ‘Inflammaging” in this patient group59, 
60. 
 
Materials and Methods- (extended methods in Supplement) 
 
Patient Samples 
The study was conducted at Great Ormond Street Hospital, London, with full ethical 
approval from the Institutional Review Board (12/LO/1186). Medium-sized muscular arteries, 
omental (OM), mesenteric (MA) or inferior epigastric (IE), routinely removed and discarded in 
the course of planned surgery were collected from CKD5-5D patients at the time of catheter 
insertion or renal transplantation and compared with disease-free, age-matched children 
(controls) undergoing intra-abdominal surgery.  The demographic details and baseline calcium 
load in the vessel wall are shown in Table S1.  Freshly isolated vessel rings were paraffin 
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embedded or cultured ex vivo in control or calcifying media for 7 days as previously described33.  
VSMCs were grown by explant culture as previously described61. Cells were counted in 
triplicate at each passage to ensure equivalent plating densities and to determine growth rates 
and used between passages 4-10 for comparisons.  All experiments, except where indicated, 
were performed on at least 3 independent VSMC isolates from each patient group (Table S2). 
 
Antibody Array 
Antibody arrays (RayBio, human cytokine antibody array VI and VII, catalog No. AAH-
CYT-6/-7) were performed using conditioned media from control (n=2) and dialysis (n=2) 
patient VSMCs.  Signals were normalized and quantified using densitometry and the signal ratio 
of control versus dialysis calculated.  ELISA or qRT-PCR for verification was performed as 
previously15.   
 
Clinical Studies  
Simultaneous vascular imaging and blood tests were performed in children with CKD5 (n = 
11) and those on dialysis (n = 24). Vascular measures were performed in all children above 5 
years of age (n=8 CKD5 and n=23 dialysis patients).  Applanation tonometry for aortic PWV 
and 64-slice spiral CT scan were performed using methods previously described.28  Vascular 
scans were performed by a single blinded operator before a mid-week session of hemodialysis or 
after overnight cycling peritoneal dialysis. Serum levels of BMP2, IL-6 and OPG were 
determined using ELISA (R & D Systems) according to manufacturer’s instructions. 
 
Statistical Analysis 
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Shapiro-Wilk test was used to test for normalcy of data before one-way ANOVA or 
Kruskal-Wallis tests were used to determine the significance of differences among groups as 
appropriate. Student’s t or Mann-Whitney U tests were used to assess differences between means 
as appropriate. Spearman correlation tests were used for correlation analyses. Statistical Package 
for Social Sciences Software  (SPSS) and GraphPad software were used for statistical 
computations.  A p value < 0.05 was considered to indicate a significant difference. 
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Figure Legends 
 
Figure 1. Vessels from children with CKD show elevated levels of oxidative DNA damage 
and senescence markers. (A) Immunohistochemistry and quantification for 8-oxo-dG showed a 
significantly increased percentage of VSMCs with oxidative DNA damage in vessels from 
predialysis (CKD5) and dialysis (CKD5D) patients compared with controls. Positive nuclei are 
arrowed, boxed inset shows enlargement. Bar=100µm (B) Immunohistochemistry showing 
increased p21 and p16 nuclear staining in predialysis (CKD5) and dialysis (CKD5D) vessels 
compared with controls. Note the nuclear staining (arrowed and insets). Bar=50µm (C) The 
percentage of positively stained cells/nuclei for p21 was significantly higher in both CKD5 and 
CKD5D when compared to control vessels while p16 was only significantly elevated in dialysis 
vessels. (Graphs show mean +/- SE, ANOVA) M: media, Ad: adventitia. 
 
Figure 2. VSMCs from dialysis vessels senesce early and show elevated levels of DNA 
damage in vitro. (A-C).  VSMCs grown from dialysis patients showed premature senescence 
compared to cells from controls as shown by (A) slower growth rates (B) SAβG staining, and 
(C) elevated levels of p16 at equivalent passage number. Representative data from n=3 control 
and dialysis isolates is shown. Bar=50µm (D) Immunofluorescence staining for γH2AX and 
pATM/ATR shows dialysis VSMCs have increased DNA damage signalling compared to 
control cells at equivalent early (P6) passage (positive nuclei arrowed). Bar=10µm (E) The 
percentage of γH2AX and pATM/ATR positive nuclei was significantly higher in dialysis 
VSMCs compared to both control and predialysis (CKD5).  Each bar represents mean ± SE, 
(*** p < 0.001, dialysis vs control and dialysis vs pre-dialysis, ANOVA). (F) Western blot 
showing increased γH2AX and pATM/ATR protein levels in dialysis (n=3, patients 04,34,51) 
	18		
VSMCs compared to CKD5 (n=2, patients 07,40) and control (n=2, patients 20,39) VSMCs at 
equivalent passage number. P, passage number. (G) Comet assays confirm increased DNA 
damage in dialysis VSMCs with an increased percentage of cells with comet tails (arrowed in 
inset showing dialysis VSMCs) compared to control cells at equivalent passage (* p < 0.05, n = 
3, Students t-test). Bar=10µm 
 
Figure 3. Elevated Ca/P caused oxidative stress and increased oxidative DNA damage in 
CKD vessels. (A) Immunofluorescence staining for γH2AX and pATM/ATR indicates that Ca/P 
promoted DNA damage (arrows indicate positive nuclei). Bar=10µm.  (B) The percent of 
γH2AX and pATM/ATR positive nuclei in response to Ca/P media is similar to doxorubicin and 
hydrogen peroxide treatments and significantly higher compared to baseline VSMCs.  Each bar 
represents mean ± SE (*** p < 0.001 compared to baseline). Bar=10µm (C) Western blotting 
shows an increase in γH2AX and pATM/ATR protein levels in calcifying media equivalent to 
doxorubicin and hydrogen peroxide treatments. (D) Immunohistochemistry for 8-oxo-dG shows 
that calcifying media promotes an increase in 8-oxo-dG staining in CKD5-5D vessels.  (E) 
Quantification shows that calcifying media significantly increases 8-oxo-dG positive nuclei in 
CKD5 (p = 0.04; n = 4) and dialysis (p = 0.001; n = 4) vessels with a greater increase in dialysis 
vessels despite similar baseline levels of oxidative DNA damage. The effect of Ca/P on control 
VSMCs was not significant (p = 0.08; n = 4).  
 
Figure 4. Dialysis VSMCs showed impaired DNA damage repair.  (A,B) 
Immunofluorescence showing elevated levels of DNA damage in dialysis VSMCs (arrowed) 24 
hours after washout of the DNA damage agent doxorubicin.  In contrast control VSMCs are 
mostly repaired at this stage.  Quantification shows both γH2AX and 53BP1 foci are elevated. A 
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high percentage of cells with >5 53BP1 foci is indicative of persistent DNA damage and failure 
of	repair. n=3 iolates/group.  ANOVA (*p<0.05, **p<0.01).  Bar=10µm. 	
 
Figure 5. VSMCs from dialysis patients show increased osteogenic differentiation and 
calcification. (A) qRT-PCR shows that VSMCs from dialysis patients have reduced expression 
of SM markers and increased expression of osteogenic markers when compared to control 
VSMCs. Each bar represents mean ± SE, Students t-Test. (B) Alizarin Red staining shows 
VSMCs from dialysis vessels are more prone to calcify than VSMCs from control vessels in 
response to calcifying medium for 7 days. Each bar represents mean ± SE. (* p < 0.05, 
ANOVA). (C) qRT-PCR shows that VSMCs from dialysis patients have significantly elevated 
mRNA expression of the osteogenic markers Runx2 and BMP2 in response to calcifying media 
when compared to control media. Each bar represents mean ± SE , (* p < 0.05, ANOVA). 
 
Figure 6. Dialysis VSMCs show increased senescence in response to calcifying media.  (A 
and B) VSMCs were incubated in control, Ca (2.7mM), P (2.5mM) or Ca/P supplemented 
serum-free medium for 16 hours and stained for SA-βG.  Increased staining was observed in 
response to elevated Ca/P or P alone in dialysis VSMCs (*** p < 0.001, ANOVA). Bar= 100µm 
(C) Western blot shows that in response to elevated Ca/P p16 is increased in dialysis VSMCs 
but not in control VSMCs.  p21 levels did not consistently change in either group.  Blots 
representative of n=3 isolates/group. 
 
Figure 7.  Inhibition of DNA damage signalling reduces calcification and expression of 
SASP factors in dialysis VSMCs. (A and B) Control and dialysis VSMCs were treated with 
osteogenic media in the presence or absence of the ATM inhibitor Ku55933.  Alizarin red 
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staining shows that after 5 days dialysis but not control VSMCs had calcified and calcification 
of dialysis cells was decreased by ATM inhibition. (*p<0.05 ANOVA) (C) qRT-PCR showing 
levels of expression of the SASP factors BMP2, IL6 and OPG in control and dialysis VSMCs.  
Note the higher levels of these factors in dialysis VSMCs at baseline. ATM inhibition using 
siRNA decreased elevated levels of the SASP factors BMP2, OPG and IL6 in dialysis VSMCs 
(pink) with little or no effect on control VSMCs (green). Effectiveness of ATM siRNA 
knockdown compared with control siRNA was equivalent for both control and dialysis VSMCs.  
Mean +/- SE, ANOVA, *p<0.05. 
 
Figure 8. Children with CKD show elevated SASP factors correlating with vascular 
stiffness. (A and B) Serum levels of BMP2 and IL6 in children with CKD5 (n = 11) and those 
on dialysis (n = 24) showing significantly higher levels of both markers in children on dialysis. 
In children with CKD5 and those on dialysis who were above 5 years of age (n = 31), BMP2 and 
OPG correlated with aortic pulse wave velocity (PWV) measured by applanation tonometry (C 
and D), showing significant correlation between these markers and PWV. (E)  Coronary artery 
calcification (CAC) was measured by multi-slice CT scan and patients were divided into 2 
groups: those with calcification (n = 8) and those who did not have calcification (n = 16).  The 
median (range) CAC score was 149 (43 to 2019) in the calcification group and 7/8 calcified 
patients were on dialysis. Children with CAC had significantly higher levels of BMP2, OPG and 
IL6 compared to those without calcification (p<0.0001; Multiple ANOVA). Comparing 
individual factors both BMP2 and IL6 were significantly elevated in the calcified group while 
OPG was not (p values for unpaired t-test are indicated on legend). 
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Supplementary Material 
 
Supplementary Figure Legends 
 
Supplementary Figure S1:  VSMCs from dialysis patients senesce early in culture. 
Graph showing the spread for passage number at senescence for VSMC isolates from control 
and CKD patients as listed on Supplementary Table S2.    Note isolates listed as growing for 
>30 passages had not yet undergone senescence at this stage.  Only a limited number of CKD5 
predialysis isolates were tested so further analyses were mostly restricted to CKD5D dialysis 
isolates. 
 
Supplementary Figure S2:  Induction of oxidative stress in VSMCs treated with 
osteogenic Ca/P media.  Lucigenin chemiluminescence assays shows that Ca/P media 
stimulates reactive oxygen species (ROS) production in VSMCs cultured in serum free 
conditions to a similar level as hydrogen peroxide treatment. Control shows VSMCs in BSA 
only. Data shown for two different VSMC isolates (A and B) and performed in triplicate. 
 
Supplementary Figure S3.   VSMCs from children on dialysis upregulate p16 in response 
to extracellular P and Ca/P.  A.  VSMCs from control and dialysis patients were exposed to 
control and calcifying media containing elevated levels of Ca and P.   Two experimental pairs 
of samples are shown.  Set 1 (left side): 1 year old male control patient (renal artery) passage 
11 and 1 year old dialysis patient (renal artery) passage 10. Set 2 (right side): 8 month old 
control patient (omental artery) passage 8 and 9 year old dialysis patient (inferior epigastric 
artery) passage 7.  Note that dialysis VSMCs have higher base line levels of p16 and a trend to 
increase p16 expression in response to P and Ca/P media.  In contrast p21 levels show no clear 
pattern of response.  BMP2 levels are also elevated in dialysis VSMCs regardless of treatment.  
B.  Quantification of Western blots by densitometry shows a clear trend for Ca/P to increase 
p16 protein levels in dialysis patient VSMCs exposed to short term Ca/P treatment.  Mean +/- 
SD. n=4 isolates/group. 
 
Supplementary Figure S4: Antibody Array analysis shows dialysis VSMCs secrete 
increased levels of SASP factors compared with controls. (A).  Representative image of an 
antibody array showing pattern of cytokine secretion by control and dialysis VSMCs.  Arrow 
indicates example of elevated cytokine in dialysis sample. (B).  Table showing ranking of the 
abundance of selected SASP factors based on density normalized to control samples on each 
array.  (C). Table showing the fold increase in SASP factors secreted from dialysis VSMCs 
compared to control.  
 
Supplementary Figure S5: ELISA shows dialysis VSMCs secrete elevated levels of 
osteogenic factors compared with control cells.  ELISA showing increased levels of IL6 and 
OPG in the conditioned media (CM) of two age-matched representative cell isolates from a 
control 8.5 year old male (8.5M) and dialysis 9 year old male (9M) patient measured at the 
same passage number.   
 
Supplementary Figure S6:  Children with CKD show increased serum levels of osteogenic 
factors correlating with time on dialysis. In children on dialysis (n = 24) IL6 levels increased 
with increasing time on dialysis (A). IL6 levels also showed a modest correlation with both 
BMP2 and OPG (B and C). 
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Supplementary Tables 
 
Supplementary Table S1.   Patient vessel samples analysed by immunohistochemistry. 
Supplementary Table S2.  Patient samples used in VSMC growth studies in vitro.	
 
 
Supplementary Materials and Methods 
 
Supplementary References 
 
 
Supplementary information is available at Kidney International's website. 
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